Purpose: To develop a high resolution microarray based method to detect single- and multiexons gene deletions and duplications. Methods: We have developed a high-resolution comparative genomic ...
Agilent Technologies Inc. has announced that scientists using an Agilent custom-designed comparative genomic hybridization (CGH) array have sequenced the entire gene map of a Korean male. An ...
Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...
Purpose: Small supernumerary marker chromosomes are centric chromosomal segments that, by definition, cannot be characterized unambiguously by conventional chromosome banding. Marker chromosomes are ...
Microarray based comparative genomic hybridisation (array CGH) is a new technology with uses developing in various diagnostic areas within the NHS. One important context is the investigation of ...
Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients. Background: Advanced ovarian clear cell carcinomas (OCCCs) are notoriously drug ...
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
Microarrays have been a mainstay of the scientific research community for nearly a decade but given the more stringent demands for accuracy and reliability, have not been as closely embraced in the ...
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results